Setmelanotide (Imcivree)
FDA-approved · Grade C
Goals
weight-loss
Evidence
3 RCT / 3 animal / 2 in vitro
Routes
injectable-sc
WADA
No
FDA
Approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.